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ABSTRACT: Glucose, O2, and nitric oxide (NO) were monitored in real time
in the prefrontal cortex of freely moving animals using microelectrochemical
sensors following phencyclidine (PCP) administration. Injection of saline
controls produced a decrease in glucose and increases in both O2 and NO.
These changes were short-lived and typical of injection stress, lasting ca. 30 s for
glucose and between 2 and 6 min for O2 and NO, respectively. Subchronic PCP
(10 mg/kg) resulted in increased motor activity and increases in all three analytes
lasting several hours: O2 and glucose were uncoupled with O2 increasing rapidly
following injection reaching a maximum of 70% (ca. 62 μM) after ca. 15 min and
then slowly returning to baseline over a period of ca. 3 h. The time course of
changes in glucose and NO were similar; both signals increased gradually over
the first hour post injection reaching maxima of 55% (ca. 982 μM) and 8% (ca.
31 nM), respectively, and remaining elevated to within 1 h of returning to baseline levels (after ca. 5 and 7 h, respectively). While
supporting increased utilization of glucose and O2 and suggesting overcompensating supply mechanisms, this neurochemical data
indicates a hyperfrontal effect following acute PCP administration which is potentially mediated by NO. It also confirms that
long-term in vivo electrochemical sensors and data offer a real-time biochemical perspective of the underlying mechanisms.
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Functional imaging studies in schizophrenic patients havesuggested reduced frontal lobe activity, that is, reduced
glucose utilization and decreased regional cerebral blood flow
(rCBF),1−4 especially during cognitive tasks involving the
prefrontal cortex such as working memory or verbal fluency.5,6
This hypofrontality was first report by Ingvar and Franzeń in
19741 and has been highly controversial since then with
conflicting findings being reported in the literature right up to
the present day.5−7 While neuroimaging measures of
metabolism and rCBF traditionally reflect the average activity
across an anatomically defined “region of interest”, or more
recently identification of clusters of significant activation using
voxel-by-voxel comparisons across the entire brain,4 they do
not provide direct in situ neurochemical information on the
potential molecular underpinnings of hypofrontality. In
addition, the technique, while ideally suitable to cognitive
testing in humans, is not amenable to such testing in rodents
due to the need to anaesthetize the experimental subjects.
The aim of the current study, therefore, was to investigate
whether these specific issues could be addressed using long-
term in vivo electrochemistry. LIVE involves the detection of
substances in brain extracellular fluid (ECF) using electro-
chemistry with implanted amperometric sensors. By implanting
a microelectrode (sensor) in a specific brain region, applying a
suitable potential profile and recording the resulting Faradaic
current, changes in the concentration of a variety of ECF
species can be monitored. This allows investigations of the
functions of specific chemicals in neuronal signaling, drug
actions, and well-defined behaviors. It offers excellent spatial
(e.g., 10−200 μm) and temporal (millisecond) resolutions, and
a major advantage of long-term stability (continuous
monitoring in vivo over several weeks).8−10
We have previously reported the in vitro11−17 and in
vivo13,15,17−19 characterization of several sensors (e.g., glucose,
O2 and nitric oxide (NO)) developed to study brain energy
metabolism. Operational characteristics such as sensitivity,
selectivity, response time, limit of detection, etc., were
characterized in detail for each device and their target substrate.
The sensors were then subsequently used to study brain
function in different application (e.g., pharmacological and
behavioral) studies.20−24 We have also shown that the
measured tissue O2 signal can serve both as an index of
changes in blood flow, 25 and of the magnitude of the blood
oxygenation level dependent (BOLD) fMRI response, thus
providing a reliable awake animal surrogate of human fMRI
experimentation, and an effective translational tool which can
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better enable the comparison of preclinical and clinical
research.26 In the present study we have explored the effects
of hypofrontality induced using phencyclidine (PCP), a
noncompetitive inhibitor of the NMDA receptor, on
extracellular glucose, O2 and NO monitored in real-time in
freely moving animals using our previously developed LIVE
sensors.
■ RESULTS AND DISCUSSION
LIVE Neurochemical Monitoring. LIVE sensors enable
continuous real-time monitoring of a variety of neurochemicals
in freely moving behaving animals where both gross and fine
details can be recorded. For example, typical prolonged
recordings of tissue O2 during day and night are shown in
Figure 1. Observed changes can be rapid, occurring over
periods ranging from seconds to minutes, or more prolonged,
lasting one or more hours. The former tends to be associated
with physiological phenomena such as grooming, feeding, and
even sleep (see Figure 2), while the latter occurs mainly with
periods of intense activity (see Figure 1B). For O2, both are
reflective of the fact that the measured real-time [O2] is the
dynamic balance between supply and utilization. Such changes
in signal (nA) can be converted to units of pressure (mmHg,
often used to represent pO2,
15,27 using post in vivo calibration
data and literature reported concentration and pressure data
associated with the air-saturated [O2] at 37 °C:
28 the maximum
increases of 22 nA (grooming, Figure 2A), 26 nA (feeding/
drinking, Figure 2B) and 76 nA (sleep, Figure 2C) correspond
to ca. 25 μM O2, 29 μM O2 and 84 μM O2, or 18, 24, and 63
mmHg, respectively.
The recent finding that brain tissue O2 monitored using a
microelectrochemical sensor in behaving animals can act as a
surrogate for BOLD fMRI responses in humans26,29,30 opens
the possibility of studying, in animal models, controversial
hypotheses or paradigms where data has primarily come from
clinical studies. Hypofrontality is one such example. Ingvar and
Franzeń reported rCBF measurements in their original paper
and found a hypofrontal rCBF distribution pattern at rest in
chronic deteriorated schizophrenics.1 Since then, while resting
hypofrontality has been replicated in a number of studies,31−33
there have also been many conflicting reports.34,35 This may in
part be explained by the potential for substantial variance in the
resting state from individual to individual because of the
heterogeneity of patient samples.36,37 Also, some reports
suggest that the ability of schizophrenic patients to recruit
the prefrontal cortex decreases when they were stimulated with
a frontal cognitive challenge.36,38 However, like resting
hypofrontality, this task-related or activation hypofrontality
has not been consistently replicated.39 While the debate has
primarily concentrated on issues such as lack of standard resting
Figure 1. Typical examples of continuous real-time in vivo recordings
of brain tissue O2 during six-hour periods covering morning/afternoon
(A, 10 am to 4 pm) and evening/night (B, 6 pm to 12 am, gray lines
represent simultaneously monitored motor activity).
Figure 2. Typical examples of changes (shaded areas) in baseline in
vivo brain tissue O2 signals associated with naturally occurring
grooming (A), feeding/drinking (B), and sleep (C). All data recorded
during morning/afternoon periods (10 am to 4 pm).
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baselines, application of a divergent array of cognitive tasks,
clinical presentation and medication status, there is also the
possibility that the different rCBF measuring techniques (e.g.,
133Xenon inhalation, single photon emission tomography
(SPECT), positron emission tomography (PET) and fMRI)
used may be contributing to the confounding results. Motion
restriction and the potentially stressful injection of radio-
isotopes are characteristics of these techniques and may
themselves alter rCBF in both the resting and activation states.
Such issues have recently been addressed by Hoshi et al. who
used near-infrared time-resolved spectroscopy (NIRS) to study
resting and activation hypofrontality in a cohort of schizo-
phrenic patients and age-matched controls.37 Interestingly, their
results indicated that a key factor in determining a positive or
negative outcome was duration of illness with resting
hypofrontality being characterized as a chronically developed
feature of the disease potentially associated with anatomical
and/or functional changes in frontal microcirculation. Indeed,
this would be in agreement with the original report of Ingvar
and Franzeń.1 While NIRS is a technique which is relatively
insensitive to head motion and does not require potentially
stressful injections, it is not readily applicable to behaving
animals. In addition, while it does enable the observation of
dynamic changes in rCBF, it does not facilitate measurement of
other metabolic parameters such as glucose and O2.
Effect of Saline. As PCP was administered systemically we
first performed control experiments involving normal saline
(NaCl 0.9%) injections. The signals for all three analytes
exhibited short-lived changes associated with the injection
stress. Glucose decreased by 0.02 ± 0.01 nA from a baseline of
0.43 ± 0.09 nA (P = 0.0160), representing a maximum decrease
of 5% (ca. 13 μM) after 39 ± 3 s (n = 4). The signal returned to
baseline levels after 93 ± 5 s (n = 4). The O2 reduction current
increased to a maximum of −168.5 ± 17.1 nA (32% (ca. 38
μM), P = 0.0030) after 33 ± 7 s and returned to baseline levels
(−127.1 ± 14.6 nA) after 111 ± 12 s (n = 4). A similar increase
was observed in NO which reached a maximum of 4.0 ± 0.8 pA
(2% (ca. 2.5 nM), P = 0.0077) after 2.2 ± 0.4 min and returned
to baseline (266 ± 34 pA) after 5.9 ± 1.3 min (n = 5). There
was no significant difference in the baseline signals before and
after the brief injection effects with the baseline values
remaining stable for up to 60 min post injection: P = 0.0696
(glucose), P = 0.2396 (O2), and P = 0.0504 (NO). A typical
example of saline induced changes in the NO signal is shown in
Figure 3A. Similar brief injection effects for saline admin-
istration have also been observed for glucose,40 O2
40 and NO18
monitored using LIVE sensors implanted in the striatum. The
stress of the injection stimulates neuronal activation,41
increasing rCBF and thus O2, and decreasing glucose through
an increase in neuronal glucose utilization.
Effect of PCP. Typical data for glucose and O2 recorded
over several hours using sensors implanted in the prefrontal
cortex following administration of PCP (10 mg/kg) is shown in
Figure 4. Simultaneously recorded motor activity is also shown
and highlights the expected locomotor hyperactivity associated
with this dose of PCP.42,43 There was an initial brief decrease in
glucose following injection which lasted several (ca. 18)
minutes and was concomitant with the start of the increase
in motor activity. This was followed by a gradual increase to a
maximum of 4.21 ± 0.28 nA after 72.8 ± 16.5 min, representing
an increase of 55 ± 7% (ca. 982 μM) from a baseline level of
2.75 ± 0.20 nA (P < 0.0001, n = 15). The signal then remained
elevated for several hours before returning to a preinjection
baseline of 2.63 ± 0.14 nA (P = 0.2981) 275.0 ± 34.1 min after
injection. Oxygen immediately began to rise following injection
reaching a maximum of −164.1 ± 4.4 nA after 16.1 ± 2.7 min,
representing an increase of 70 ± 4% (ca. 62 μM) from a
baseline level of −97.1 ± 2.3 nA, (P < 0.0001, n = 15). The
signal then began to decrease reaching a preinjection baseline of
−96.9 ± 2.3 nA (P = 0.2981) 198.7 ± 13.9 min after injection.
NO levels also increased following injection (see Figure 3B)
reaching a maximum of 401 ± 60 pA 45 ± 6 min post injection,
representing an increase of 8 ± 2% (ca. 31 nM) from a baseline
level of 375 ± 56 pA (P = 0.0447, n = 13). In a similar manner
to glucose the signal then remained elevated for several hours
before rapidly returning to a preinjection baseline of 379 ± 95
pA (P = 0.3085) 470 ± 82 min after injection. The total change
in signal for each analyte in response to both saline and PCP
was calculated as the area under the curve: Glucose −0.06 ±
0.01 nA × min (saline, n = 4), 275.0 ± 34.1 nA × min (PCP, n
= 15); O2 −278.1 ± 23.4 nA × min (saline, n = 4), 6792.3 ±
Figure 3. (A) Typical example of the effect of a saline injection on
nitric oxide monitored in the prefrontal cortex of a freely moving rat.
Inset: Close-up of the injection region. (B) A typical example of the
effect of the administration of PCP (10 mg/kg) on nitric oxide. Time
zero indicates the point of injection.
Figure 4. Typical examples of the effects of the administration of PCP
(10 mg/kg) on glucose (green) and O2 (red) monitored
simultaneously in the PFC of a freely moving rat. Time zero indicates
the point of injection. The gray lines represent motor activity
(movement) recorded using a passive infrared detector.
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374.7 nA × min (PCP, n = 15); NO −0.045 ± 0.008 nA x min
(saline, n = 5), 23.4 ± 1.4 nA × min (PCP, n = 5). These
results clearly show that LIVE sensors can provide continuous
real-time metabolic data in an animal model of psychosis. Not
only that, they also enable simultaneous recording of multiple
data sets facilitating a direct comparison and investigation of
their inter-relationship.
The observed increase in O2 suggests an initial rapid increase
in rCBF,40 and given that the changes were coincident with
increased locomotor activity it is likely to be due to increased
delivery to cope with the increased energy demand. The slower
increase in glucose is also more likely to reflect increased supply
rather than a decrease in metabolic activity, and hence glucose
utilization as observed in resting state hypofrontality. Since the
O2 signal represents the balance between supply from the
vasculature and utilization, the subsequent declining signal
suggests a decrease in supply rather than increased utilization,
given the continuous locomotor hyperactivity and the fact that
the glucose signal remains elevated during this declining period.
The uncoupling and the difference in the time scales for the
changes in glucose and O2 is something we have observed
previously with anesthetics40 and during mild neuronal
activation induced by a 5 min period of stimulation (tail
pinch).22 While some of the supplied glucose may be coming
from the increased blood flow it is likely that there is a
significant contribution from another source or intermediate
compartment. Evidence suggests that this is likely to involve
astrocytes, which now appear to play a central role in the
delivery of metabolic substrates.44,45
One of the current theories of hypofrontality suggests that a
hyper-glutamatergic state of the PFC corresponds to hypo-
activation which is caused by a disruption of glutamatergic
signaling of the NMDA receptor complex.5 This acute NMDA
receptor antagonist model is in apparent contradiction to the
profound increases in cortical excitatory activity observed
following NMDA receptor blockade, that is, hyperfrontality, or
increases in glucose utilization and blood flow in the PFC.46−49
However, recent animal studies using techniques directly
analogous to those used in patients have demonstrated that
repeated or chronic treatment with PCP evokes neuroadaptive
processes more relevant to schizophrenia than acute treatment
and that these processes manifest as hypofrontality.50 The
glucose and O2 data presented herein support a hyperfronal
effect following subchronic treatment. The NO data suggests a
potential role for this gaseous second messenger of the NMDA
receptor in mediating this process. Indeed, it has previously
been implicated in the mechanism of PCP psychosis23,51,52 as
well as cognitive dysfunction.53,54 It has also recently been
reported that the hyperactive state of glutamatergic neurons in
the PFC may be mediated through inhibition of GABAergic
interneurons by NO.5 One must also remember that NO
interacts with the dopaminergic as well as the serotonergic
systems, thereby linking glutamatergic to monoaminergic
signaling. In fact disruption in the latter suggests that
hypofrontality is a delayed consequence of PCP administration;
repeated PCP exposure has been reported to induce a selective
reduction in basal and stress-evoked dopamine utilization in the
PFC, and rats previously subchronically treated with PCP were
found to be impaired in a spatial working memory task.55
Interestingly, these dopaminergic and cognitive deficits were
observed following withdrawal from PCP, and as such were
reported to be due to drug-induced neurochemical changes
rather than direct drug effects.
■ CONCLUSIONS
This study presents real-time neurochemical measurements of
glucose, O2, and NO recorded using microelectrochemical
sensors in an animal model of schizophrenia known to induce
hypofrontaility. Injection of saline produced small short-lived
changes in all three analytes while PCP resulted in locomotor
hyperactivity and increased signals lasting several hours. The
time course of changes in glucose and NO were similar; both
signals increased gradually over the first hour post injection and
remained elevated to within an hour of returning to baseline
levels (after ca. 5 and 7 h, respectively). Oxygen on the other
hand increased rapidly following injection reaching a maximum
after ca. 15 min and then slowly returning to baseline over a
period of ca. 3 h. While the presented results provide direct in
situ real-time neurochemical and behavioral information on the
effects of PCP administration validating the application of LIVE
sensors in such studies, they do not support a hypofrontal effect
for subchronic doses and reinforce the notion of disturbed
prefrontal NO neurotransmission playing a role in schizo-
phrenia. Future work will investigate whether a metabolic
hypofunction exits under chronic conditions and if post chronic
PCP administration is a better model for schizophrenia, as has
been suggested for dopamine.
■ METHODS
Chemicals and Solutions. Saline solutions (0.9%) were prepared
by dissolving 0.9 g of NaCl in 100 mL of doubly distilled water.
Phencyclidine hydrochloride (PCP, Sigma Chemicals, St. Louis, MO)
was dissolved in saline and administered via systemic (intraperitoneal,
glucose and O2; subcutaneous, NO) injection. A dose of 10 mg/kg in a
volume of 2 mL was used based on previously published studies.43,55
All standard chemicals (NaCl, NaH2PO4, and NaOH) were used as
received and purchased from Sigma-Aldrich Ireland Ltd. (Dublin).
Sensor Preparation. Sensors for O2 (carbon paste disk electrodes;
8T Teflon-coated Ag wire, 200-μm bare diameter, 270-μm coated
diameter, Advent Research Materials, Suffolk, U.K.), glucose (5T
Teflon-coated Pt disk electrodes modified with poly(o-phenylenedi-
amine) and glucose oxidase; 125 μm bare diameter, 160 μm coated
diameter, Advent Research Materials), and NO (5T Teflon-coated Pt
disk electrodes modified with Nafion) were prepared following
previously reported protocols.15,18,19 In vitro calibrations were
performed over physiologically relevant concentrations (glucose, 0−
10 mM; O2, 0−240 μM; NO, 0−1 μM) in a standard three-electrode
glass electrochemical cell containing 15 mL of phosphate buffer saline
(PBS) solution, pH 7.4 (0.15 M NaCl, 0.04 M NaH2PO4, and 0.04 M
NaOH). A saturated calomel electrode (SCE) was used as the
reference electrode, and a Pt wire served as the auxiliary electrode.
Instrumentation and Software. Constant potential amperom-
etry (CPA; −650 mV (O2), +700 mV (glucose), and +900 mV (NO))
was performed in all electrochemical experiments using a low-noise
custom designed potentiostat (Biostat IV, ACM Instruments,
Cumbria, U.K.). Data acquisition was performed with a notebook
PC, a PowerLab interface system (ADInstruments Ltd., Oxford, U.K.),
and LabChart for Windows software (ADInstruments Ltd.).
All data are presented as mean ± standard error (SEM). Data is
reported as baselines, maximum/peak responses (currents) and
durations (time). To facilitate ease of comparison area under curve
(AUC) analysis was performed to quantify the observed changes in the
sensor signals. For PCP the AUC was calculated by integrating the
current for each analyte over the period during which it deviated from
the baseline. For saline the AUC was calculated for a fixed period of 10
min. For presentation (in Figures 3 and 4), data was normalized to the
respective baseline levels for each sensor. All analysis was performed
using Microsoft Excel 2007 and the commercial packages Prism
(version 5.01) and InStat (GraphPad Software Inc., La Jolla, CA). The
statistical significance of differences observed was calculated using
Student’s t tests (two-tailed paired or unpaired observations where
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appropriate). Values of P < 0.05 were considered to indicate statistical
significance.
Surgical Procedures. Male Wistar rats weighing 200−300 g were
anesthetized with the volatile anesthetic isoflurane (4% in air for
induction, 1.5−3.0% for maintenance; IsoFlo, Abbott, U.K.) using a
Univentor 400 Anaesthesia Unit (AgnTho’s AB, Sweden). Once
surgical anesthesia was established, animals were placed in a stereotaxic
frame and the sensors implanted following a previously described
procedure.22 Coordinates for the prefrontal cortex with the skull
leveled between bregma and lambda were as follows: A/P + 3.2, M/L
± 0.8 from bregma, and D/V −4.2 from dura. Sensors were implanted
bilaterally in each animal in either glucose/O2 or NO/NO
combinations. A reference electrode (8T Ag wire, 200 μm bare
diameter; Advent Research Materials) was placed in the cortex and an
auxiliary electrode (8T Ag wire) attached to one of the support screws
(see below). The reference potential provided by the Ag wire in brain
tissue is very similar to that of the SCE. The electrodes were fixed to
the skull with dental screws and dental acrylate (Associated Dental
Products Ltd., Swindon, U.K.). Postoperative analgesia was provided
in the form of a single injection (0.1 mg/kg, s.c.) of Vetergesic
(buprenorphine hydrochloride, Reckitt and Colman Pharmaceuticals,
Hull, U.K.) given immediately following the surgery. Animals were
allowed to recuperate for 24 h after surgery and were assessed for good
health according to published guidelines56 immediately after recovery
from anesthesia and at the beginning of each day. This work was
carried out under license in accordance with the European
Communities Regulations 2002 (Irish Statutory Instrument 566/
2002, Amendment of Cruelty to Animals Act 1876).
Experimental Conditions in Vivo. Rats were housed in large
plastic bowls, in a windowless room under a 12 h light, 12 h dark cycle,
lights coming on at 8 a.m., with free access to water. Food was
available ad libitum. All experiments were carried out with the animal
in its home bowl. Implanted sensors were connected to the
potentiostat after the 24 h recuperation period, through a six-pin
Teflon socket (MS363, Plastics One, Roanoke, VA), and a flexible
screened six core cable (363−363 6TCM, Plastics One) which was
mounted through a swivel (SL6C, Plastics One) above the rat’s head.
This arrangement allowed free movement of the animal which
remained continuously connected to the instrumentation. After
application of the appropriate applied potential each animal was
given a further 24 h before experiments were begun in order to ensure
that the background currents for the electrodes were completely
stabilized. A low-pass digital filter (50 Hz cutoff) was used to eliminate
mains AC noise and all data was recorded at 4 Hz.
Animal motor activity (movement) was recorded using a passive
infrared (PIR) detector (Gardscan QX PIR, Gardiner Technology,
Queensway, Rochdale, OL11 1TQ, UK) positioned directly over the
home bowl and connected to a dedicated channel in the data
acquisition system (PowerLab/LabChart). Movement originating in
the field of view of the sensor activates the “alarm” function of the
detector thereby sending a count (voltage trigger) to the PowerLab
which appears as a 0/1 (off/on) spike in the LabChart trace. This
facilitates the direct correlation of movement data with the in vivo data
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